How RECCE 327 is Leading the Way as a Potential Robust Solution to Sepsis and Superbugs

How RECCE 327 is Leading the Way as a Potential Robust Solution to Sepsis and Superbugs

Product not yet rated

Recorded On: 09/29/2022

Session Description:

Recce’s new class of synthetic anti-infectives, including RECCE 327, have a universal mechanism of action with the ability to overcome hyper-cellular mutation of bacteria and viruses. In this sponsored session, learners will review the unique qualities of Recce anti-infectives, including that their potency does not diminish even with repeated use. Learners will also review the ways in which Recce Pharmaceuticals continues to strengthen and expand its product pipeline of therapeutic options for ‘difficult to treat’ bacterial and viral infections.

This session was originally recorded in September 2022 as part of Sepsis Alliance Summit.

No CE credits are offered for this sponsored session. Content was determined by the sponsor.

Session Sponsor:

Sepsis Alliance gratefully acknowledges the support provided by Recce Pharmaceuticals for this sponsored session.


James Graham

Managing Director & Chief Executive Officer

Recce Pharmaceuticals

James Graham is the Chief Executive Officer of Recce Pharmaceuticals. Mr. Graham was formerly Executive Director and has extensive experience in marketing, business development, and commercialization of early-stage technologies with global potential. Mr. Graham has served on Recce’s Board of Directors for six years and has invested in almost every capital raise to date, with a focus on expanding Recce’s commercial opportunities and clinical initiatives.

Session Title: Recce Pharmaceuticals Sponsored Session: Addressing AMR and the Global Incidence of Sepsis with a New Class of Anti-Infectives

Session Day/Time: Wednesday, September 27, 2023, 3:25 PM - 3:55 PM EST

Access Session

Components visible upon registration.